Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hegde Sheila M, Wang Xiaowen, Bhatia Ankit, Peña-Peña Maria Luisa, Sherrid Mark V, Figueiredo Estevao Lanna, Arad Michael, Barriales-Villa Roberto, Choudhury Lubna, Claggett Brian L, Coats Caroline J, de Barros Correia Edileide, Costabel Juan Pablo, Elliott Perry M, Silva Enciso Jorge E, Garcia-Pavia Pablo, Ge Junbo, Ho Carolyn Y, Lakdawala Neal K, Lewis Gregory D, Maron Martin S, Martinez Matthew W, Masri Ahmad, Maurer Mathew S, Michels Michelle, Mitter Sumeet S, Pino Moreno Jesus E, Nagy Viktória, Olivotto Iacopo, Owens Anjali T, Poulsen Steen H, Rader Florian, Rowin Ethan J, Ruda Maria, Schulze P Christian, Sikand Nikhil, Spertus John A, Zhao Xiaoyan, Divanji Punag H, Heitner Stephen B, Jacoby Daniel L, Kupfer Stuart, Malik Fady I, Salazar-Mendiguchía Joel, Wohltman Amy, Zhuo Shu, Solomon Scott D, ACACIA-HCM Investigators
Аннотация
METHODS: Symptomatic patients with nonobstructive hypertrophic cardiomyopathy were randomized 1:1 to receive aficamten (range, 5-20 mg, titration based on left ventricular [LV] ejection fraction) or placebo for up to 72 weeks (end of treatment). The effect of aficamten on echocardiographic measures at 36 weeks (time of primary end point) and end of treatment was assessed with linear regression models adjusted for baseline values, intracavity obstruction, and baseline atrial fibrillation.
RESULTS: Among 517 participants (mean±SD: age, 55±16 years; 54% female, 75% White, 13% Asian), mean baseline LV ejection fraction was 68±4% with abnormal measures of diastolic function. Compared with placebo, aficamten decreased LV ejection fraction (-4.6% [-5.5, -3.6]; P<0.001) at 36 weeks and increased LV volumes. Aficamten improved measures of diastolic function, including lateral e' and septal e' velocities, at 36 weeks (0.9 cm/s [0.6, 1.2] and 0.7 cm/s [0.4, 0.9], respectively; P<0.001 for both) and at end of treatment (0.9 cm/s [0.5, 1.2] and 0.9 cm/s [0.6, 1.1], respectively; P<0.001 for both) and septal E/e' by end of treatment (-1.4 [-2.1, -0.6]; P<0.001, respectively). Peak tricuspid regurgitation velocity improved at 36 weeks (-10.4 cm/s [-19.9, -1.0]; P=0.030) with a sustained effect through end of treatment. Left atrial volume index did not significantly improve at 36 weeks (-1.3 [95% CI, -2.6, 0.04]; P=0.06) but showed a trend towards improvement with longer treatment exposure (-1.7 [-3.2, -0.3]; P=0.022). Aficamten demonstrated incremental improvements in measures of LV structure and function compared to placebo as doses were increased, with improvement in diastolic indices evident by week 2 of titration.
CONCLUSIONS: In patients with nonobstructive hypertrophic cardiomyopathy, aficamten improved echocardiographic measures of diastolic function. These findings suggest that the benefits of aficamten extend beyond the effects of LV outflow tract gradient reduction observed in prior studies.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06081894.